November 7, 2025
The Washington Post recently published an article featuring Rena Conti, Associate Professor of Markets, Public Policy, and Law, discussingg President Donald Trump’s new agreements with Eli Lilly and Novo Nordisk to lower the cost of GLP-1 weight-loss drugs such as Ozempic, Wegovy, and Mounjaro.
The plan would make certain Medicare patients eligible for a $50 monthly co-pay and allow uninsured consumers to purchase the medications for about $350 per month through the upcoming TrumpRx platform, expected to launch in 2026.
Experts say the initiative could expand access but provides only modest savings to Medicare and builds on pricing mechanisms established under Biden’s Inflation Reduction Act. Conti noted that the move is likely to apply downward pressure on drug prices overall, as insurers push for similar terms.
“We would expect commercial payers to demand to use these posted prices as ceiling prices,” Conti said.
Health Secretary Robert F. Kennedy Jr. praised the deal as an important step in the “Make America Healthy Again” effort, while emphasizing that tackling the root causes of obesity remains essential.
